Plicamycin , ≥95% , 18378-89-7

Synonym(s):
Aureolic acid;Mithramycin A - CAS 18378-89-7 - Calbiochem;Plicamycin;Plicamycin, Mithramycin

CAS NO.：18378-89-7

Empirical Formula: C52H76O24

Molecular Weight: 1085.15

MDL number: MFCD00135618

EINECS: 634-048-4

PRODUCT Properties

• Melting point: 180-183 °C
• alpha: D20 -51° (c = 0.4 in ethanol)
• Boiling point: 761.72°C (rough estimate)
• Density: 1.1576 (rough estimate)
• refractive index: 1.6500 (estimate)
• storage temp.: 2-8°C
• solubility: Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 10 mg/ml)
• form: Powder
• pka: 4.54±0.60(Predicted)
• color: Red to brown
• Merck: 13,7619
• BRN: 5236667
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
• EPA Substance Registry System: Plicamycin (18378-89-7)

Description and Uses

Mithramycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It is well known as the aureolic acid antitumor antibiotic that inhibits both cancer growth and bone resorption by cross-linking GC-rich DNA, thus blocking binding of Sp-family transcription factors to gene regulatory elements. Transcription of c-Src, a gene implicated in many human cancers and required for osteoclast-dependent bone resorption, is regulated by the binding of Sp factors to specific elements in its promoter. Therefore, this gene represents an important anticancer target and a potential lead target through which mithramycin displays action against osteoclastic bone resorption via an unknown mechanism. Hazards of handling this drug by the health-care personnel arise from a combination of factors: (1) its inherent toxicity and (2) the extent to which workers are exposed to the drug in the course of carrying out their duties. This exposure may be through inadvertent ingestion of the drug on foodstuffs (e.g., workers’ lunches), inhalation of drug dusts or droplets, or direct skin contact. Mithramycin has been used to decrease bone resorption in patients with humoral hypercalcemia and Paget’s disease.

Mithramycin was the first of the aureolic acid class of antitumour antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302
• Precautionary statements: P301+P312+P330
• Hazard Codes: Xn,T+
• Risk Statements: 22-26/27/28
• Safety Statements: 45-38-36/37/39-28A-22
• RIDADR: 3249
• WGK Germany: 3
• RTECS: PZ2800000
• F: 10
• HazardClass: 6.1(b)
• PackingGroup: III
• HS Code: 29419090
• Hazardous Substances Data: 18378-89-7(Hazardous Substances Data)
• Toxicity: LD50 in mice, rats (mg/kg): 2.14, 1.74 i.v. (Slavik, Carter)